Could a daily injection tame two rare inflammatory diseases?
NCT ID NCT07706868
First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This study tests the drug anakinra in Chinese patients with two related inflammatory conditions: Systemic Juvenile Idiopathic Arthritis (SJIA) in children and Adult-Onset Still's Disease (AOSD) in adults. Participants receive a daily injection under the skin for 48 weeks. The goal is to see if anakinra reduces symptoms like fever, rash, and joint pain, and to check for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a drug called anakinra (Kineret), given as a daily injection under the skin
- What this could lead to
- If successful, this could confirm anakinra as a safe and effective treatment option for Chinese patients with these rare inflammatory diseases.
- What could go wrong
- This is a relatively small, open-label study without a placebo group, so results may be less definitive. Side effects from anakinra can include injection site reactions and increased risk of infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT ONSET STILL'S DISEASE (AOSD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.